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Abstract
Background: Alcohol is a major risk factor for burden of disease and injuries globally. This paper presents a
systematic method to compute the 95% confidence intervals of alcohol-attributable fractions (AAFs) with exposure
and risk relations stemming from different sources.
Methods: The computation was based on previous work done on modelling drinking prevalence using the
gamma distribution and the inherent properties of this distribution. The Monte Carlo approach was applied to
derive the variance for each AAF by generating random sets of all the parameters. A large number of random
samples were thus created for each AAF to estimate variances. The derivation of the distributions of the different
parameters is presented as well as sensitivity analyses which give an estimation of the number of samples required
to determine the variance with predetermined precision, and to determine which parameter had the most impact
on the variance of the AAFs.
Results: The analysis of the five Asian regions showed that 150 000 samples gave a sufficiently accurate estimation
of the 95% confidence intervals for each disease. The relative risk functions accounted for most of the variance in
the majority of cases.
Conclusions: Within reasonable computation time, the method yielded very accurate values for variances of AAFs.
Background
Alcohol consumption is a major risk factor for burden
of disease and injuries globally [1,2] as demonstrated by
the Comparative Risk Analyses (CRA) within the Global
Burden of Disease and Injury (GBD) Studies [2,3]. To
estimate the impact of alcohol consumption on infec-
tious and chronic diseases, alcohol attributable fractions
(AAFs) are calculated [4] and applied to the number of
deaths or number of incident cases [5].
Up until now, confidence intervals (CIs) have not been
presented in the CRA for the estimates of alcohol-attri-
butable health harms. While there are methods to calcu-
late uncertainty around AAFs when both exposure and
risk relations are derived from the same cohort [6,7], no
such methods exist for the case where both exposure and
risk relations stem from two different meta-analyses (for
general concerns and considerations see [5,8,9] and the
Discussion section below). This article aims to fill this
gap, and for the first time will present a method to calcu-
late CIs for the new AAFs modelling methodology used
in the 2005 CRA study for chronic diseases by region, sex
and age (see [4] for a description of the AAF modelling
methodology and [10] for a comparison of the new AAF
modelling methodology with previous methods.)
Alcohol is related to many disease categories [5]. Since
globally morbidity and mortality can only be reliably esti-
mated for broad disease or injury categories, the GBD is
restricted to 126 distinct broad disease or injury categories
http://www.globalburden.org/GBD_Study_Operations_
Manual_Jan_20_2009.pdf, of which 31 are causally related
to alcohol [5]. We will first be using exposure measures
and relative risks for disease categories from the 2005
CRA study for which a meta-analysis providing a continu-
ous relative risk function exists to estimate AAFs [5], and
then will explain the methodology to construct CIs for
these AAFs. This paper will focus on the Asian regions as
an illustration of our results. Asia presents an interesting
mix of low income and high income regions and allows us
to illustrate succinctly our methodology.
* Correspondence: gerrit.gmel@gmail.com
1Centre for Addiction and Mental Health (CAMH) 33 Russell Street, Toronto,
Ontario, M5S 2S1, Canada
Full list of author information is available at the end of the article
Gmel et al. BMC Medical Research Methodology 2011, 11:48
http://www.biomedcentral.com/1471-2288/11/48
© 2011 Gmel et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Methods
This method has two main steps: (1) calculation of the
AAFs, and (2) calculation of the variance for the AAFs.
Information from multiple sources, all of which carries a
certain degree of uncertainty, is required in order to cal-
culate the AAFs. This information is outlined below.
Definition of regions
Regions were defined in accordance with the 2005 GBD
study [11]. Countries were grouped into regions which
were defined by their geographical location and epidemio-
logical profile which includes child and adult mortality
levels and major causes of death. Neither income nor
population of the countries in a region had an impact on
the grouping. For the purpose of illustrating the method,
we restricted the analysis to the five Asian regions contain-
ing the countries listed below:
￿ Asia Pacific, High Income: Brunei Darussalam,
Japan, Republic of Korea, Singapore
￿ Asia Central: Armenia, Azerbaijan, Georgia,
Kazakhstan, Kyrgyzstan, Mongolia, Tajikistan, Turk-
menistan, Uzbekistan
￿ Asia East: China, Democratic People’s Republic of
Korea, Hong Kong, Macao, Taiwan
￿ Asia South: Afghanistan, Bangladesh, Bhutan,
India, Nepal, Pakistan
￿ Asia Southeast: Cambodia, Christmas Island, Cocos
Island, Indonesia, Lao People’sD e m o c r a t i cR e p u b l i c ,
Malaysia, Maldives, Mauritius, Myanmar, Philippines,
Reunion, Seychelles, Sri Lanka, Thailand, Timor
Leste, Vietnam
Population estimates for each region by country for
2005 were based on estimates obtained from the 2008
revisions of the United Nations Population Division [12].
Definition of age categories
Three age categories were used in the CRA study: 15 - 34,
35 - 64 and 65 or greater; we limited our study to the age
category of 15 to 34 years. Ages were clustered so that
results would be comparable with the 2005 GBD study.
Measures of alcohol consumption
Adult per capita consumption is calculated by adding
together the estimated recorded and unrecorded alcohol
consumption [13,14]. The variance of an estimate of
recorded consumption was based on estimates from dif-
ferent sources (for example, government data, industry
data, Food and Agriculture Organization), which are
usually quite similar. The main sources for determining
unrecorded consumption are home production, alcohol
intended for industrial, technical, and medical uses, and
illegal production or importation of alcohol. The
variance of an estimate of unrecorded consumption is
larger in comparison to that of recorded consumption
and there are usually only sparse sources for informa-
tion on unrecorded consumption which is often based
on limited empirical evidence [14,15]. Since uncertainty
of unrecorded adult per capita consumption is not pro-
vided in the 2005 CRA study, we assumed the standard
deviation of unrecorded adult per capita consumption
was proportionally five times larger than the standard
deviation for recorded adult per capita consumption.
The prevalence of lifetime abstainers and former drin-
kers was estimated from a population-weighted average
of surveys in the respective regions by sex and age.
Using the proportion of current drinkers we calculated
the per capita consumption of alcohol per current drin-
ker, which was used in modelling alcohol consumption.
T h ev a r i a n c eo fp r e v a l e n c ec a nb ee s t i m a t e du s i n ga
binomial distribution, as illustrated below in the Statisti-
cal procedures section.
Modelling alcohol consumption
Using comparable studies, involving 1001 distributions
from 66 countries by sex and age, it can be shown that
the distribution of alcohol consumption for the drinking
population is modelled best using the gamma distribu-
tion [4]. It is well known that population surveys under-
estimate true consumption, and thus data from surveys
have to be triangulated with estimates of adult per
capita consumption, which are often based on sales data
[4,13]. To be conservative, we assumed that 80% of this
registry-based estimate reflected the true adult per
capita consumption; this level was chosen to account for
the alcohol wasted and not consumed (for example, bro-
ken bottles and quantities left over in glasses) and for
the underestimation of true consumption in medical
epidemiological studies, which were used in the meta-
analyses that estimated the relative risk functions.
A regression of the above-mentioned studies showed a
strong relationship between mean and standard devia-
tion (for men and women, the explained variance of
standard deviation was greater than 90%). This relation-
ship allows us to compute the standard deviation of an
upshifted distribution very easily. Finally, this method
relies on the assumption that the proportion of alcohol
consumed by the various sex and age groups derived
from surveys is accurate [4].
Measures of relative risk
The relative risk functions for each chronic disease were
derived using a series of meta-analyses which used frac-
tional polynomial regression [5] separated by sex and,
where possible, by morbidity and mortality (e.g. liver
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polynomial representing the relative risk function are
called beta-coefficients. The uncertainty of the relative
risk beta-coefficients is expressed by a covariance matrix
(obtained from the meta-analyses). Of the diseases with
which alcohol is associated, these associations take one
of three forms: 1) exponential, 2) linear, or 3) J-shaped.
Figure 1 provides a plot of the relative risk for liver cir-
rhosis for men as an example of a disease having an
exponential relationship with alcohol consumption,
figure 2 is a plot of the relative risk for hemorrhagic
stroke (mortality) for men which has a linear association
with alcohol consumption, and figure 3 outlines the
relative risk for coronary heart disease for men as an
example of a disease having a j-shaped relationship with
alcohol consumption.
Step 1: Calculation of the AAF
This step requires calculating the daily consumption
AAF estimates, and will be outlined below.
Alcohol-attributable fractions (AAFs)
The AAF for a given infectious or chronic disease can
be expressed as follows [4]:
AAF =
Pabs + PformRRform +
∞ 
0
P(x)RR(x)dx − 1
Pabs + PformRRform +
∞ 
0
P(x)RR(x)dx
where Pabs is the proportion of lifetime abstainers,
Pform is the proportion of former drinkers among the
population, and RRform is the relative risk of the latter
proportion. P(x) represents the prevalence of drinking at
level × (in grams per day, mo d e l l e db yag a m m af u n c -
tion), and RR(x) is the relative risk at this level com-
pared to lifetime abstainers. In the CRAs, AAFs are
usually calculated separately by sex, age, and sometimes
by ethnic groups. In our study of Asian regions, AAFs
were computed by region (see below), sex and age.
We did not use this mathematical expression in its
original form when estimating the AAFs for several rea-
sons. Firstly, a person whose daily consumption exceeds
150 grams per day is highly unlikely to consume this
amount over a long period of time. Therefore, to be
Figure 1 Risk relationship between average daily intake of
alcohol and liver cirrhosis for men.
Figure 2 Risk relationship between average daily intake of
alcohol and hemorrhagic stroke for men.
Figure 3 Risk relationship between average daily intake of
alcohol and coronary heart disease for men.
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cated at 150 grams per day. Secondly, when there is
truncation at 150 grams per day, the gamma distribution
needs to be normalized by adding a coefficient in front
of the probability density function to ensure that the
area under this function will integrate to 1 between 0
and 150 grams of alcohol per day.
Step 2: Calculation of the variance of the AAF
This step requires calculating the variance of the AAF
estimates with risk data, and will be outlined below.
In order to derive 95% CIs for AAFs, two paths can be
taken. The first one consists of deriving the expression
for the variance of the AAF by taking into account all
the errors of the parameters on which it depends, and
subsequently computing the CI for the AAF. This
approach, although mathematically accurate, is too com-
plex in our case. Indeed, the AAF depends on the rela-
tive risk function, the prevalence of former drinkers and
abstainers, and the distribution of consumption among
drinkers. Since errors in these values and functions are
non-trivial, it is virtually impossible to compute the
variance of AAFs algebraically.
The second approach is simpler, but less accurate, and
requires more computation. A number (we will call it N
for simplicity) of random sets of the lowest level para-
meters (the parameters from which all other values are
derived) are generated, namely the coefficients of the
relative risk functions, the adult per capita consumption
and the prevalence of former drinkers and lifetime
abstainers. Each random set of lowest level parameters
will then yield an AAF value for a total of N AAFs for
each region, sex, age group and disease. The variance of
t h eNA A F sw i l la p p r o a c ht h et r u ev a r i a n c ea sN
increases. This corresponds to calculating the variance
of an AAF using a Monte Carlo-type method [18].
In order to generate these random samples for each
lower level parameter, the distribution, mean and var-
iance of each parameter must be known. The following
paragraphs elucidate the methods used to determine the
properties of each parameter.
Statistical procedures
The simulations were implemented in R (version: 2.10.1,
refer to “Additional file 1: Example of R - code for simula-
tions” for an example of the code) and the numerical
errors inherent in any computational program were
neglected (for example, the error (uncertainty) which is
added by using numerical integration in calculating the
AAFs was not taken into consideration for our variance
calculations). The random normal generation of adult per
capita consumption for the drinking population some-
times yields values that are negative or zero, which are fac-
tually impossible. In these instances, the value was set to
0.001 to symbolize very low consumption. Mathematically,
a zero mean consumption would transform the gamma
distribution into a Dirac distribution located at 0. In addi-
tion, drinkers would have a consumption of 0 grams per
day which is not compatible with the definition of current
drinkers.
The generation of adult per capita consumption
assumes a random normal distribution as we have no
information about an alternative distribution. Very low
per capita consumption occasionally obtained by the ran-
dom normal generation caused some additional trouble
during the computation. The method used in R to
numerically integrate a function results in errors and
incorrect results if the corresponding function is either
constant or approximately constant. When a gamma dis-
tribution has mean values that approach 0, it is spread
very little (according to the linear relation between mean
and standard deviation). This makes the distribution
approximately constant after the initial spike close to the
origin. These functions cannot be integrated and R pro-
duces an error message. As this problem occurs only
when consumption levels are estimated to be very low,
the assumption was made that under such circumstances
the AAF calculated with this set of parameters would
also be 0. This method assumes that former drinkers are
not at an elevated risk for the given disease.
In general, the scale (θ) and shape () parameters of the
gamma distributions are correlated and the covariance
has to be taken into account when generating random
samples of θ and . This difficulty is avoided considering
the fact that  i sac o n s t a n ti no u rc a s e( i ts h o u l db e
noted, however, that the constant is different for men
and women). According to previous work by Rehm and
colleagues:
κ =
μ2
σ2 =
1
β2
where b is the coefficient linking the standard devia-
tion to the mean. Therefore,  is independent of region,
age group and θ. In order to generate a random sample
of , the variance is found using the delta method:
Var(κ)=
4 ∗ Var(β)
β6
The generation of θ parameters is more difficult. Esti-
mates of θ are different for each region, sex and age
group since θ depends on the mean and variance of
each gamma distribution. The generation of θ was per-
formed in 2 steps: first, we generated a random sample
of adult per capita consumption values from a normal
distribution using the mean and standard deviation of
this distribution, and second we generated a random
sample of the prevalence of lifetime abstainers and
former drinkers.
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drinkers in each case follow binomial distributions, their
variances, considering only sampling variation, can be
expressed as follows:
Var = p ∗ (1 − p)/n
T h ee f f e c t i v es a m p l es i z eo fe a c hs u r v e yu s e dt oe s t i -
mate the proportion of lifetime abstainers and former
drinkers was assumed to be 1000 (to reflect an average
sample size for surveys of 6000 per population, assum-
ing that the three age-sex categories have equal cell
size). Using these values, it is possible to calculate the
corresponding proportion of drinkers, the mean con-
sumption per sex-age category and, finally, θ,w h i c hi s
then simply given by θ =
μ
κ
.
To account for the error of the final relative risk func-
tions, N instances of each beta-coefficient were gener-
ated based on the covariance matrix. Each of these N
relative risk functions obtained with one instance of
each beta-coefficient was then assigned to one set of
parameters defining the population (mean adult per
capita consumption, proportion of abstainers and pro-
portion of former drinkers). The relative risk functions
were assumed to be the same for all regions and age
groups.
As previously mentioned, each random set of lowest
level parameters described above were then used to cal-
culate an AAF value for a total of N AAFs for each
region, sex, age group and disease. The variance of the
NA A F sw a su s e da st h et r u ev a r i a n c eo ft h eA A F
estimates.
Main analysis, sensitivity analyses, and evaluation of the
impact of each variable on the variance
As an example of this method, we calculated the AAFs
for males aged 15 to 34 in the Asian regions; however,
the above-described methods can also be used to calcu-
late the AAFs for females. In addition, to demonstrate
that partial AAFs and variances for these AAFs can be
calculated for different consumption levels, we estimated
the AAFs for cardiovascular diseases, ischemic stroke
and diabetes for males aged 15 to 34 who are low con-
sumers of alcohol (0 to 39.9 grams of alcohol per day),
moderate consumers of alcohol (40 to 59.9 grams of
alcohol per day) and heavy consumers of alcohol (60 to
150 grams of alcohol per day).
In order to accurately estimate the variance of an AAF
we need to determine how many samples are required.
Too few samples could lead to inaccurate results, while
increasing the number of samples increases computing
times and may require a larger amount of storage. Addi-
tionally, after a large number of iterations, the gain in
accuracy is very small and does not provide new
substantial information. Therefore, in order to deter-
mine the optimal number of random samples needed to
calculate the variance of an AAF, a sensitivity analysis
was performed. Since our samples are randomly gener-
ated, each set of samples is independent and allows us
to collect a large amount of data relatively quickly. To
decrease computation time, the code was adapted to
generate 150 sets, each containing 1000 AAF estimates
for each region (by sex and age and disease). The var-
iance of each set of 1000 AAFs can then be averaged to
estimate the variance of larger sets. By systematically
increasing the number of sets used to calculate the aver-
age variance, we estimated the number of samples
required for the variance to settle.
N e x t ,w ec a r r i e do u ta na n a l y s i st oe s t i m a t et h e
impact of each component on the final variance using
the same sets of randomly generated variables, but in
different arrangements. For the purposes of this analysis,
only 1000 sets of lowest level parameters (see above for
a definition) were generated.
To calculate the impact on the variance of each para-
meter, the AAFs were calculated for a set of parameters in
which only the parameter tested was randomly generated
while the other parameters were held constant. The var-
iance obtained from the generated AAFs then represented
the variance induced by the error of this single variable.
Since the AAF function is non-linear, the variances
obtained cannot simply be added together to obtain the
total variance. To simplify the interpretation of the results,
each contribution was normalized so that the sum equal-
led the total variance obtained as a result of the computa-
tion explained in the previous paragraphs. For the purpose
of our analysis, the computations of the proportion of
total variance explained by different variables were
restricted to men in the five Asian regions defined above.
To compare in terms of dose response and magnitude
the AAFs calculated using the new methodology by
Rehm and colleagues to the method used in the 2004
CRA study [19], we calculated the partial AAFs for car-
diovascular diseases and diabetes of multiple drinking
categories for men in the five above defined Asian
regions. The drinking categories were defined as
1) 0 to < 0.25 grams per day, 2) 0.25 to < 20 grams per
day, 3) 20 to < 40 grams per day, and 4) 40+ grams per
day. The relative risks used in the 2004 CRA study for
cardiovascular diseases and diabetes were obtained from
Gutjahr et al., [20], Reynolds et al., [21], Carrao et al.,
[22], and Corrao et al., [23].
Considerations of computing time
A sRi sas i n g l e - c o r ep r o g r a m ,s p l i t t i n gu pt h ec o d ei n t o
different parts (for example, by sex and age) allows a user
to take advantage of the multi-core architecture of mod-
ern central processing units. Additionally, when dealing
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splitting of the program into different sub-programs by
age, sex and region allows a user to reduce the size of the
data sets, and therefore to speed up the computations.
Results and Discussion
Per capita estimates by sex and region are shown in
table 1, and prevalence of drinkers, former drinkers, and
current drinkers are shown in table 2. We observed that
on average men drink approximately 4.25 times more
than women, and that regions with higher income levels
and higher standards of living exhibited increased levels
of alcohol consumption. The variance of per capita con-
sumption is also much more important proportionally
to the point estimate for countries with lower standards
of living. The exhibited proportions of current drinkers
bear out these conclusions.
Table 3 depicts the point estimates of each disease for
the male population of the five described Asian regions,
including their 95% CIs. When an AAF estimate was
close to zero, the CIs also crossed zero, making it
impossible to determine if the AAF was truly positive or
negative. The use of 150 000 random samples provided
us with enough precision to confidently estimate the CIs
to two decimal places. In addition, the partial AAFs and
their variances can be calculated for low consumers of
alcohol (0 to 39.9 grams of alcohol per day), moderate
consumers of alcohol (40 to 59.9 grams of alcohol per
day), and heavy consumers of alcohol (60 to 150 grams
of alcohol per day). Table 4 outlines the AAFs for cardi-
ovascular diseases, ischemic stroke and diabetes by con-
sumption amount.
Impact on total variance of each parameter
As shown in Figure 4, the variance of the relative risk
functions was, on average, the largest contributor to the
variance of the AAFs. This is the case for disease cate-
gories such as ischemic heart disease and lower respira-
tory infections, where the variance of the betas of the
relative risk function for these diseases is large [5]. For
oral cavity cancer, oesophageal cancer, larynx cancer,
pancreatitis, tuberculosis, liver cirrhosis and hemorrha-
gic stroke, adult per capita consumption was the largest
contributor to the variance observed in the AAFs. We
can speculate that either more research has been under-
taken concerning those diseases leading to more precise
risk functions, or that simple relationships can be more
accurately estimated with fewer errors.
Examples of changes in variance as the sample size
increases
Figures 5 and 6 illustrate the change in the estimated
variance when more samples are added to the analysis.
When looking at the convergence of the variance, in the
case of oral cavity and pharynx cancer, approximately
60 000 to 70 000 random samples are required to accu-
rately estimate the variance of the AAFs. For the case of
tuberculosis in Asia Central, we found that the variance
converged only after 100 000 random samples were
used. Therefore, in order to insure the convergence of
each variance estimate considering a small safety mar-
gin, around 150 000 sample points are needed. It should
be noted, however, that if the CIs are to be determined
with a maximum error of ± 1 on the second decimal,
the precision of the variance only needs to be greater
than 2.6e-5 which is usually achieved after as few as
40 000 samples.
Comparison of AAFs using new and old methodologies
Table 5 outlines the new methodology of calculating the
AAF by Rehm and colleagues [4] and the methodology
used in the 2004 CRA study. The AAFs for the new
methodology are very close to the AAFs estimated using
the old methodology for the same drinking groups; how-
ever, the inclusion of former drinkers in the new metho-
dology increases the total AAF for each region. Also, it
should be stated that prevalence of consumption in this
sensitivity analysis was based on the gamma distribution
for both methodologies (once used continuous and once
categorical), whereas the original 2004 CRA study used
a different form of up estimation [13].
Conclusions
In this paper we have presented a method to estimate
uncertainty around AAFs and illustrated our results
using data for men aged 15 to 34 years in several Asian
regions. The use of 60 000 to 70 000 Monte Carlo
Table 1 Per capita alcohol estimates (in grams per day)
Region Men S.E.
1 Asia, Pacific (high income) 13.51 1.57
2 Asia, Central 10.62 1.73
3 Asia, East 9.88 1.42
4 Asia, South 3.80 0.80
5 Asia, Southeast 5.21 0.79
Table 2 Prevalence of current drinkers, former drinkers
and lifetime abstainers by region, and age
Region Sex lifetime
abstainer
S.E. former
drinker
S.E. current
drinker
S.E.
1 M 0.05 0.01 0.07 0.01 0.87 0.01
2 M 0.23 0.01 0.13 0.01 0.64 0.02
3 M 0.13 0.01 0.15 0.01 0.72 0.01
4 M 0.73 0.01 0.11 0.01 0.17 0.01
5 M 0.56 0.02 0.17 0.01 0.27 0.01
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Asia, Pacific
(High Income)
Asia,
Central
Asia,
East
Asia,
South
Asia,
Southeast
DISEASE AAF lower bound upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
Oral Cavity and Pharynx
Cancer
43.00% 35.50% 50.40% 41.80% 32.60% 51.00% 25.70% 19.60% 31.80% 16.40% 10.20% 22.60% 22.70% 16.50% 28.90%
Oesophagus Cancer 25.90% 20.60% 31.30% 25.60% 18.70% 32.60% 14.90% 11.30% 18.50% 9.30% 5.80% 12.80% 13.50% 9.80% 17.20%
Colon Cancer 4.40% 1.60% 7.10% 4.70% 2.00% 7.40% 4.70% 2.70% 6.70% 2.70% 1.50% 4.00% 4.90% 2.80% 7.00%
Rectum Cancer 7.40% 5.10% 9.60% 7.40% 5.00% 9.80% 6.10% 4.20% 8.00% 3.40% 2.20% 4.70% 5.90% 3.90% 8.00%
Liver Cancer 13.40% 8.40% 18.40% 12.60% 7.50% 17.60% 9.10% 6.00% 12.10% 4.90% 2.90% 6.90% 8.10% 5.30% 10.90%
Larynx Cancer 27.70% 21.70% 33.60% 27.30% 19.70% 34.90% 15.80% 11.90% 19.80% 9.90% 6.10% 13.80% 14.30% 10.30% 18.30%
Coronary Heart Disease -13.80% -36.40% 8.80% -5.40% -24.10% 13.30% -7.50% -16.60% 1.60% 0.40% -4.20% 5.10% -0.40% -6.80% 6.00%
Epilepsy 24.90% 17.80% 32.10% 24.60% 16.00% 33.30% 14.50% 10.30% 18.70% 8.90% 4.90% 13.00% 13.00% 8.80% 17.20%
Conduction Disorder and
other Dysrhythmias
11.70% 7.30% 16.10% 11.40% 6.70% 16.10% 8.10% 5.40% 10.70% 4.60% 2.70% 6.40% 7.50% 4.90% 10.00%
Pancreatitis 19.90% 11.80% 28.00% 27.00% 12.80% 41.10% 7.80% 5.10% 10.50% 10.20% 3.40% 17.00% 11.00% 6.30% 15.70%
Lower Respiratory Infections 9.80% 2.50% 17.00% 9.60% 2.30% 16.90% 7.20% 3.40% 10.90% 4.10% 1.60% 6.50% 6.80% 3.50% 10.10%
Hemorrhagic Stroke -
Morbidity
15.80% 12.20% 19.30% 15.70% 10.80% 20.70% 11.20% 4.70% 17.80% 6.70% 2.10% 11.30% 10.70% 2.90% 18.50%
Hemorrhagic Stroke -
Mortality
14.20% 9.00% 19.50% 14.20% 8.00% 20.50% 10.60% 3.80% 17.40% 6.20% 1.50% 11.00% 10.10% 2.20% 18.10%
Ischemic Stroke - Morbidity -4.70% -11.80% 2.40% 1.80% -4.40% 8.00% -2.00% -11.40% 7.40% 3.00% -1.90% 7.80% 4.10% -5.00% 13.10%
Ischemic Stroke -4.30% -11.30% 2.70% 2.30% -3.80% 8.40% -2.00% -11.40% 7.40% 3.10% -1.80% 8.00% 4.20% -4.80% 13.20%
Tuberculosis 22.10% 12.50% 31.70% 23.20% 13.00% 33.40% 9.90% 5.30% 14.40% 8.40% 4.00% 12.80% 11.80% 6.50% 17.10%
Diabetes Mellitus -5.30% -17.80% 7.30% -0.20% -11.50% 11.20% -2.50% -10.30% 5.20% 1.40% -2.80% 5.60% 1.50% -5.40% 8.30%
Hypertension 17.50% 12.30% 22.70% 16.50% 10.30% 22.70% 8.40% 5.50% 11.40% 4.70% 2.20% 7.30% 6.80% 4.00% 9.50%
Liver Cirrhosis - Morbidity 34.20% 24.50% 43.90% 35.10% 22.60% 47.60% 19.80% 9.20% 30.50% 13.80% 4.60% 23.10% 18.80% 6.20% 31.40%
Liver Cirrhosis 57.00% 45.20% 68.90% 61.40% 45.80% 77.00% 32.10% 21.30% 43.00% 30.30% 15.10% 45.60% 34.00% 20.20% 47.80%
Computed using 150 000 sampled parameter sets.
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2Table 4 AAFs and 95% confidence intervals for the 5 Asian regions based on consumption patterns considering only the male population aged 15 - 34 years
Asia, Pacific
(High
Income)
Asia,
Central
Asia,
East
Asia,
South
Asia,
Southeast
AAF lower bound upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
AAF lower
bound
upper
bound
Low consumption (0 to 39.9
grams of alcohol per day)
Coronary Heart
Disease
-13.91% -23.33% -4.49% -7.08% -13.80% -0.37% -10.88% -19.18% -2.58% -1.55% -2.97% -0.14% -4.18% -6.43% -1.93%
Conduction Disorder
and other
Dysrhythmias
5.58% 3.76% 7.40% 3.39% 1.95% 4.82% 3.86% 2.18% 5.55% 0.81% 0.38% 1.25% 1.92% 1.31% 2.53%
Ischemic Stroke -
Morbidity
-9.24% -13.37% -5.12% -4.48% -7.51% -1.45% -8.13% -11.65% -4.62% -0.99% -1.61% -0.38% -2.84% -3.81% -1.88%
Ischemic Stroke -
Mortality
-9.27% -13.45% -5.09% -4.46% -7.55% -1.38% -8.23% -11.77% -4.69% -0.99% -1.58% -0.39% -2.85% -3.82% -1.88%
Diabetes Mellitus -7.19% -12.98% -1.40% -3.84% -8.06% 0.38% -5.49% -10.65% -0.32% -0.87% -1.76% 0.03% -2.26% -3.71% -0.81%
Hypertension 8.82% 6.98% 10.67% 5.44% 3.95% 6.94% 6.15% 4.43% 7.86% 1.33% 0.78% 1.88% 3.10% 2.37% 3.84%
Moderate consumption (40
to 60 grams of alcohol per
day)
Coronary Heart
Disease
-1.08% -4.02% 1.85% -0.88% -3.29% 1.52% -0.40% -3.88% 3.09% -0.21% -1.20% 0.77% -0.37% -1.70% 0.96%
Conduction Disorder
and other
Dysrhythmias
2.45% 1.41% 3.50% 2.05% 1.05% 3.05% 0.89% -0.29% 2.07% 0.51% 0.16% 0.86% 0.85% 0.39% 1.31%
Ischemic Stroke -
Morbidity
0.55% -0.02% 1.12% 0.47% -0.01% 0.95% 0.19% -0.48% 0.85% 0.12% -0.07% 0.30% 0.19% -0.06% 0.44%
Ischemic Stroke -
Mortality
0.69% 0.18% 1.20% 0.59% 0.14% 1.03% 0.24% -0.36% 0.84% 0.14% -0.03% 0.31% 0.24% 0.01% 0.46%
Diabetes Mellitus -0.45% -2.12% 1.21% -0.36% -1.72% 1.00% -0.17% -2.16% 1.81% -0.09% -0.64% 0.47% -0.15% -0.91% 0.61%
Hypertension 4.15% 2.71% 5.59% 3.48% 2.00% 4.96% 1.52% -0.15% 3.18% 0.87% 0.38% 1.37% 1.45% 0.85% 2.06%
Heavy consumption (60+
grams of alcohol per day)
Coronary Heart
Disease
0.22% -3.00% 3.43% 0.60% -2.47% 3.67% -0.01% -5.64% 5.61% 0.17% -3.27% 3.60% 0.08% -3.09% 3.25%
Conduction Disorder
and other
Dysrhythmias
3.71% 2.11% 5.31% 5.21% 3.46% 6.96% 0.61% -2.11% 3.33% 1.42% -0.11% 2.96% 1.35% -0.07% 2.77%
Ischemic Stroke -
Morbidity
1.91% 1.07% 2.75% 2.82% 1.91% 3.73% 0.29% -1.19% 1.77% 0.76% -0.09% 1.61% 0.69% -0.07% 1.45%
Ischemic Stroke -
Mortality
2.17% 1.26% 3.07% 3.19% 2.17% 4.21% 0.33% -1.25% 1.91% 0.86% -0.07% 1.79% 0.78% -0.02% 1.59%
Diabetes Mellitus 1.34% -0.81% 3.50% 2.31% 0.22% 4.40% 0.15% -3.72% 4.02% 0.63% -1.84% 3.11% 0.49% -1.72% 2.70%
Hypertension 6.70% 4.04% 9.36% 9.41% 6.40% 12.42% 1.11% -3.31% 5.53% 2.66% 0.04% 5.28% 2.49% 0.15% 4.84%
G
m
e
l
e
t
a
l
.
B
M
C
M
e
d
i
c
a
l
R
e
s
e
a
r
c
h
M
e
t
h
o
d
o
l
o
g
y
2
0
1
1
,
1
1
:
4
8
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
2
8
8
/
1
1
/
4
8
P
a
g
e
8
o
f
1
2samples yields stable variance estimates in most cases,
b u tw ep r o p o s et h eu s eo f1 5 00 0 0s a m p l e st oe n s u r e
stable CIs. Uncertainties about risk relations and about
total per capita consumption were identified as the main
contributors to variances of the AAFs for men aged 15 to
34 years in the five Asian regions. These variances indi-
cate that for some disease categories the dose-response
curve from alcohol has not been sufficiently researched.
The observed large variances may result from an insuffi-
cient number of underlying articles describing dose-
response or from the non-linear nature of dose-response
relationships. As some of the non-linear nature may be
caused by other dimensions of alcohol consumption (for
example, irregular heavy drinking occasions in the case
of ischemic diseases) [24,25], it will not be enough to just
conduct more epidemiological studies into the impact of
average volume of alcohol consumption on the incidence
of diseases (for an overview see [5]). Instead, other rele-
vant dimensions of alcohol consumption, which could
play a role in confounding the average volume of alcohol
consumption, should be included in the design of cohort
studies, and then should be statistically controlled for by
using, for example, meta-regression techniques [26].
One limitation of our approach was the use of adjusted
relative risks in determining AAFs. The relative risk for-
mulas we used were developed for risks only adjusted for
age (see [8,9,27]). Two arguments can be made to justify
the use of these formulas. Firstly, in risk analyses, such as
the CRA for the GBD Studies [28], almost all of the
underlying studies for the different risk factors report
only adjusted risks. Relying on unadjusted risks would
severely bias the estimated risk functions as only a small
proportion of generally older studies could be included.
Secondly, for alcohol in particular, most of the analyses
show no marked differences after adjustment for the
usual risk factors tested (see [5], and the meta-analyses
cited there). The need for adjustment to the relative risks
may change when other dimensions of alcohol consump-
tion, such as irregular heavy drinking occasions, are con-
sidered (see above).
Another limitation of the new methodology is the nat-
ure of the relative risks that are used in the CRA study.
As there is likely to be undercoverage of alcohol con-
sumption in the medical epidemiological studies upon
which the relative risks are based, modelling 100% of
adult per capita consumption will lead to biased results.
Accordingly, as coverage of alcohol consumption in these
studies is likely greater than 70% [10], we modelled alco-
hol consumption as 80% of adult per capita consumption.
This adjustment leads to lower estimates of alcohol-attri-
butable health harms [10]. Additionally, we modelled
average daily alcohol consumption from 0 to 150 grams a
day, using 150 grams as a maximum level. In very rare
cases people may drink more than 150 grams per day;
however, it is unlikely that this level of consumption
w o u l db em a i n t a i n e do v e ra ne x t e n d e dp e r i o do ft i m e
[29]. An upper limit of alcohol consumption in grams
per day may lead to an underestimation of the effects of
Figure 4 Impact of parameters of AAF on final variance.
Figure 5 Change of the estimated variance of oral cavity and
pharynx cancer in Asia, Pacific (high income) for the male
population aged between 15 and 34 years as the sample size
increases.
Figure 6 Change of the estimated variance of tuberculosis in
Asia, Central for the male population aged between 15 and
34 years as the sample size increases.
Gmel et al. BMC Medical Research Methodology 2011, 11:48
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Page 9 of 12Table 5 AAFs for the 5 Asian regions based on methods used in the 2004 CRA study and methods used in the 2005 CRA study for males aged 15 - 34 years
Asia, Pacific (High
Income)
Asia, Central Asia, East Asia, South Asia, Southeast
New
Method
Old
Method
New
Method
Old
Method
New
Method
Old
Method
New
Method
Old
Method
New
Method
Old
Method
Abstainers, Former drinkers
or very light drinkers
Coronary Heart Disease 0.71% 0.00% 1.63% 0.00% 2.93% 0.00% 1.95% 0.00% 3.68% 0.00%
Ischemic Stroke -
Morbidity
1.27% 0.00% 2.61% 0.00% 4.68% 0.00% 3.05% 0.00% 5.71% 0.00%
Ischemic Stroke -
Mortality
1.26% 0.00% 2.61% 0.00% 4.67% 0.00% 3.05% 0.00% 5.71% 0.00%
Diabetes Mellitus 0.66% 0.00% 1.43% 0.00% 2.57% 0.00% 1.68% 0.00% 3.19% 0.00%
Hypertension -0.09% 0.00% -0.04% 0.00% -0.10% 0.00% -0.01% 0.00% -0.03% 0.00%
Drinking Category I (0.25 to
< 40 grams of alcohol per
day)
Coronary Heart Disease -18.18% -20.30% -8.74% -9.52% -15.26% -17.50% -1.89% -2.04% -5.30% -5.84%
Ischemic Stroke -
Morbidity
-13.22% -8.46% -6.08% -4.03% -12.36% -7.90% -1.33% -0.90% -3.96% -2.61%
Ischemic Stroke -
Mortality
-13.25% -8.46% -6.07% -4.03% -12.46% -7.90% -1.32% -0.90% -3.96% -2.61%
Diabetes Mellitus -11.05% -4.19% -5.44% -1.91% -9.55% -4.34% -1.20% -0.43% -3.37% -1.32%
Hypertension 6.03% 7.47% 4.11% 4.35% 2.93% 5.61% 1.01% 1.04% 2.10% 2.59%
Drinking Category II (40 to <
60 grams of alcohol per day)
Coronary Heart Disease -1.08% -4.81% -0.88% -2.63% -0.40% -4.18% -0.21% -0.60% -0.37% -1.53%
Ischemic Stroke -
Morbidity
0.55% -2.30% 0.47% -0.64% 0.19% -3.27% 0.12% -0.13% 0.19% -0.72%
Ischemic Stroke -
Mortality
0.69% -2.30% 0.59% -0.64% 0.24% -3.27% 0.14% -0.13% 0.24% -0.72%
Diabetes Mellitus -0.45% -7.08% -0.36% -4.42% -0.17% -4.98% -0.09% -1.01% -0.15% -2.25%
Hypertension 4.15% 0.86% 3.48% 1.89% 1.52% -2.08% 0.87% 0.49% 1.45% 0.35%
Drinking Category III (60+
grams of alcohol per day)
Coronary Heart Disease 0.22% -3.38% 0.60% -1.49% -0.01% -3.66% 0.17% -0.33% 0.08% -1.07%
Ischemic Stroke -
Morbidity
1.91% -2.13% 2.82% 0.06% 0.29% -3.43% 0.76% 0.07% 0.69% -0.64%
Ischemic Stroke -
Mortality
2.17% -2.13% 3.19% 0.06% 0.33% -3.43% 0.86% 0.07% 0.78% -0.64%
Diabetes Mellitus 1.34% -5.20% 2.31% -3.79% 0.15% -3.98% 0.63% -0.91% 0.49% -1.68%
Hypertension 6.70% 3.95% 9.41% 7.53% 1.11% -2.25% 2.66% 2.11% 2.49% 1.53%
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2alcohol in terms of total harms, especially where alcohol
at low doses has a positive effect and at high doses has a
negative effect, such as with cardiovascular diseases,
ischemic stroke and diabetes. Such instances are limited,
however, as the risk ratios used to model the effects of
alcohol were fractional polynomials allowing us to accu-
rately characterize curvilinear risk relationships. Addi-
tionally, alcohol starts to have a negative effect well
below a consumption level of 150 grams per day and,
thus, limiting our consumption models to 150 grams per
day does not have a substantial effect on the AAFs.
Furthermore, as the upper limit of sustainable alcohol
consumption probably differs depending on the sex of
the drinker, more research is needed to define these
limits.
Our new methodology is capable of being adjusted to
take into account different parameters of alcohol con-
sumption [10]. For example, this method can easily be
modified for future research that focuses on the effects
of specific alcohol consumption patterns on the burden
of disease. In summary, future iterations of the CRA, or
similar studies, should include CIs, as our methodology
offers a feasible way to estimate the uncertainty of attri-
butable fractions for all burdens of disease.
Additional material
Additional file 1: Example of R - code for simulations.
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